VOCs in Patients With Acute Cardiogenic Chest Pain

NCT06277895 | Unknown

• 1 other identifier: KYLL-202401-047
• Study Type: interventional
• Target: 1,400
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observation study is to compare VOCs in cardiogenic chest pain population/health conditions, to answer：Establishment and promotion of the application system of emergency rapid detection of expiratory Volatile Organic Compounds (VOCs) in patients with acute cardiogenic chest pain

1. 1.VOCs levels were measured at baseline in healthy people, and markers of VOCs that could be used to identify acute cardiogenic chest pain were sought.
2. 2.The relationship between abnormal VOCs (mainly aldehydes) and prognosis of patients and the correlation with Super-score for early warning of acute heart failure.

Conditions

Acute Coronary Syndrome; Acute Aortic Syndrome

Outcome Measures

Primary Outcomes (1)

• Baseline VOCs (aldehydes) levels in healthy population

  Baseline VOCs (aldehydes) levels in healthy population

  Baseline

Secondary Outcomes (1)

• MACE in patients with cardiogenic chest pain

  From enrollment to the end of treatment at 30 days

Study Arms (2)

cardiogenic chest pain group

EXPERIMENTAL

cardiogenic chest pain group/acute coronary syndrome

Diagnostic Test: VOCs

normal group

OTHER

Healthy population

Diagnostic Test: VOCs

Interventions

VOCs DIAGNOSTIC_TEST

test the end-expiratory gas

cardiogenic chest pain group; normal group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Over 18 years old, male or female;
• Patients with acute cardiogenic chest pain (see diagnostic criteria);
• Patient\'s informed consent.
• Over 18 years old, male or female;
• Centerless cerebrovascular disease, lung disease, no abnormal liver and kidney function, no acute infection recently;
• Informed consent.

You may not qualify if:

• The patient had difficulty in collecting breath;
• Patients with terminal illness or receiving palliative care;
• Have participated in other clinical studies or consider it inappropriate to participate in this study.

Sponsors & Collaborators

• Qilu Hospital of Shandong University: lead

Study Sites (1)

Qilu hospital

Jinan, Shandong, 250012, China

RECRUITING

MeSH Terms

Conditions

Acute Coronary Syndrome; Acute Aortic Syndrome

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Aortic Diseases

Central Study Contacts

Yuan Bian, Dr.

CONTACT

+8618560083065; bianyuan@sdu.edu.cn

Xiuting Yang, Dr.

CONTACT

800-872-5327; yxt-1819@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 25, 2024
• First Posted: February 26, 2024
• Study Start: January 26, 2024
• Primary Completion: December 31, 2024
• Study Completion: December 31, 2024
• Last Updated: February 26, 2024

Record last verified: 2024-01

Locations

CN (1)